A team of researchers led by biomedical scientist Declan McCole at the University of California, Riverside, has found that the drug tofacitinib, also called Xeljanz and approved by the FDA to treat rheumatoid arthritis and ulcerative colitis, can repair permeability defects in the intestine. “Our work could help improve identification of patients who will be better responders to this drug,” said McCole, a...
